Cencora, Inc. (COR) reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.34, which beat the Zacks Consensus Estimate of 3.18 by 5%. The bottom line also improved 14.4% year over year. GAAP EPS was $2.42, up 3% from that reported in the year-ago period. Revenue Details Revenues totaled $74.2 billion, up 10.9% year over year. The top line beat the Zacks Consensus Estimate by 0.8%. Segmental Analysis U.S. Healthcare Solutions Revenues in this segment totaled $67.2 billion, up 12.2% on a y ...

Cencora, Inc. (NYSE:COR) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of Ame ...

• Disability:IN announced that Cencora earned the recognition of a "Best Place to Work for Disability Inclusion" for the second year in a row based on the company's score on the Disability Equality Index. | --- | --- | |-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | Financial highlights & fiscal 2024 guidance | | • Adj ...

Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.03%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.65 per share when it actually produced earnings of $3.80, delivering a surprise of 4.11%. Over the last four quarters, ...

Exhibit 99.1 Press Release CENCORA REPORTS FISCAL 2024 THIRD QUARTER RESULTS Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 CONSHOHOCKEN, PA, July 31, 2024 - Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 b ...

The second-quarter 2024 earnings season has just begun for the Medical sector (one of the 16 broad Zacks sectors within the Zacks Industry classification), with several MedTech players ready to release their quarterly results. The latest Earnings Trends indicates that 16.9% of the companies in the Medical sector, constituting nearly 33.8% of the sector's market capitalization, reported earnings until Jul 24. All reported companies beat on their respective earnings and revenues. Earnings increased 4.2% year ...

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Valu ...

In the last reported quarter, the company delivered an earnings surprise of 4.11%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%. The Zacks Consensus Estimate for revenues is pegged at $73.58 billion, indicating an improvement of 9.9% from the top line reported in the prior-year quarter. The consensus mark for earnings is pinned at $3.18 per share, implying growth of 8.9% from the year-ago quarter's recorded number. Sustained strong growth in spec ...

This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.40%. For Cencora, estimates have been trending higher, thanks in part to this earnings surprise history. And when you The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related ...

Professor Tim Jackson, PhD, FRCOphth, Consultant Ophthalmic Surgeon, King's College Hospital and Professor of Retinal Research, King's College London, commented, "We have waited a long time for a brand of bevacizumab that is authorized for eye use, and it is good news that LYTENAVA™ has now entered the market. This occurs subsequent to Outlook Therapeutic's clinical trial meeting its endpoint. To date, many ophthalmologists have been hesitant to use an off-label bevacizumab, when licensed products are avail ...